Running Title: SIX1 coordinates with TGF-in tumor lymphangiogenesis.
Introduction
Tumor-induced lymphangiogenesis is correlated and functionally associated with tumor metastasis and poor prognosis (1, 2) . Similar to tumor angiogenesis, lymphangiogenesis is mainly influenced by the tumor microenvironment (3) . Among a variety of factors, vascular endothelial growth factor (VEGF) C and VEGF-D are considered the key drivers of lymphangiogenesis (4) (5) (6) (7) (8) . VEGF-C is essential for the migration, survival and proliferation of lymphatic endothelial cells (LECs) (9, 10) . Additionally, VEGF-C has been found to play a critical role in tumor lymphangiogenesis and lymph-node (LN) metastasis in many tumor types (4, 11) . Nevertheless, the mechanisms underlying the modulation of VEGF-C and VEGF-D expression in the tumor milieu, as well as their effect on tumor lymphangiogenesis, have not been fully elucidated.
Transforming growth factor-(TGF-) is known to play an important role in tumor progression, including metastasis (12) . Although the precise relationship between TGF-and tumor lymphangiogenesis is not well known, recent studies suggest that TGF-1 might exert dual effects on lymphangiogenesis. TGF-1 might up-regulate VEGF-C expression in some types of cells, including tumor cells (13, 14) , implying that TGF-1 might contribute to tumor lymphangiogenesis. Conversely, TGF-1 has been found to down-regulate VEGF receptor-3 (VEGFR3) in LECs and suppress LEC properties, thus inhibiting lymphangiogenesis (15, 16) .
So far it remains unclear whether the effects of TGF-on LECs and VEGF-C-expressing cells can be modulated, and what is the final effect of TGF-on tumor lymphangiogenesis.
Sine oculis homeobox homolog 1 (SIX1) is a developmentally regulated homeoprotein that plays a crucial role in the development of various organs (17) expression in most non-neoplastic adult tissues but is frequently overexpressed in numerous malignancies (18, 19) . The overexpression of SIX1 correlates with poor clinical prognosis in a variety of cancers, including breast cancer, ovarian cancer, hepatocellular carcinoma, and rhabdomyosarcoma (20) . SIX1 has been found to transcriptionally activate the expression of multiple pro-tumorigenic genes and impair a DNA damage-induced G 2 -M checkpoint by up-regulating the expression of cyclin A1, cyclin D1 and c-Myc (21, 22) . Importantly, SIX1
has been found to enhance TGF-signaling (20) and transcriptionally activate VEGF-C expression (23) , suggesting that SIX1 may have the potential to modulate tumor lymphangiogenesis.
In cervical cancer, lymphatic vessels are the major route for tumor metastasis (24) .
Infection by high-risk human papillomavirus (HPV), the major cause of cervical cancer (25) , can significantly up-regulate SIX1 expression (26) . A recent study suggested that lymph-node metastasis in cervical cancer correlates with higher SIX1 mRNA levels in primary tumors (27) . Moreover, higher VEGF-C expression in cervical cancer is associated with higher densities of peritumoral lymphatic vessels, increased lymphatic invasion, and increased lymph-node metastasis (28) . Higher TGF-1 expression is also associated with lymph-node metastasis and poor prognosis of cervical cancer (29, 30) . Based on these premises, in this study we investigated whether SIX1 and TGF-were responsible for modulating VEGF-C expression and lymphangiogenesis in cervical cancer. Our data demonstrated that SIX1 could enhance the activation and effect of the TGF--SMAD pathway in cervical cancer cells, thus increasing VEGF-C expression to promote lymphangiogenesis. Importantly, the increased production of VEGF-C not only directly promoted lymphangiogenesis but also thwarted the 
Materials and Methods

Cells
Human cervical squamous carcinoma cell lines Siha, C33a and Caski were purchased from the American Type Culture Collection (Manassas, VA), and cultured according to their guidelines. All of these cell lines were authenticated at Shanghai Paternity Genetic Testing Center in June 2012, using short tandem repeat (STR) DNA profiling (ABI 3130xl Genetic Analyzer, Life technologies TM , USA). Human lymphatic endothelial cells (HLECs) were purchased from Sciencell (San Diego, CA), and cultured in Endothelial Cell Medium (ECM, ScienCell, USA) with 5% fetal bovine serum and endothelial growth medium supplements (VEGF-C-free). In all related experiments, the fourth passage of HLECs was used. The cells showed typical cobblestone-like morphology. More than 95% of HLECs expressed LYVE-1 and podoplanin (lymphatic markers), verified by flow cytometry.
Cell transfection
RFP/luciferase-expressing tumor cells were prepared as we described previously (31) . and "P", the first letter in the names of shRNAs, indicate neomycin-resistance and puromycin-resistance of the vector. Nshcon and Pshcon, not targeting any known gene, were used as controls. After selection with G418 and/or puromycin, the cells with stable transfection of shRNA were used for further experiments. To down-regulate the expression of SIX1, SMAD2, SMAD3 or T R1, the corresponding siRNA (RiboBio, Guangzhou) was transfected into tumor cells using Lipofectamine 2000 according to standard protocols.
Immunohistochemistry
Cervical squamous cell carcinoma (CSCC) samples were acquired by surgery from cancer patients without preoperative radiotherapy or chemotherapy, which was approved by the Ethical Committee of the Medical Faculty of Tongji Medical College. Informed consent was obtained from all subjects. The tumor samples were used for the preparation of tissue microarray (TMA, for SIX1, VEGF-C, TGF-1, TGF-2, TGF-3 and T R1 staining) at Outdo Biotech Company (Shanghai), as well as for the preparation of individual sections for LYVE-1 staining. Tissue sections were subjected to immunohistochemical analysis as described previously (32) . For semi-quantitative evaluation of protein level in tissue, an immunoreactivity-scoring system HSCORE was used (28, 31) . HSCORE 2.0 was classified as a low protein level, and HSCORE > 2.0 was classified as a high protein level. Lymphatic vessel density (LVD) was determined according to the methods described by Zoltan Gombos et al (28) and Zhang SQ et al (33) . The slides were read by two pathologists, and each data point represents the mean of the two scores. See Supplementary Methods for more details. Western blot assay was done as described previously (34) . Antibodies are described in the Supplementary Methods.
Western blot assay
In vivo lymph-node metastasis
Female NOD-SCID mice (4 weeks old) were purchased from Beijing HFK Bio-Technology Co, LTD. (Beijing, China) for studies approved by the Committee on the Ethics of Animal Experiments of Tongji Medical College. The mice were maintained in the accredited animal facility of Tongji Medical College. An orthotopic xenograft model of cervical cancer was performed as described previously (35, 36) . Tumor growth was dynamically monitored in living mice by optical imaging of luciferase activity using the IVIS SPECTRUM system (Caliper, Xenogen USA). See Supplementary Methods for more details.
Metastases were detected when primary tumors reached about the same size. Tumor cells that had metastasized to the lymph-nodes were identified by detecting tumor-expressed RFP under an SZX16 dissecting microscope (Olympus). Pelvic para-aortic lymph-nodes were analyzed [4 lymph-nodes/mouse, as suggested previously (36) ]. The percentage of metastasis-positive lymph-nodes (the ratio of positive lymph-nodes to total lymph-nodes) in each mouse, and the incidence of lymph-node metastasis (the ratio of the mice with lymph-node metastasis to total mice) in each group were calculated.
Assay of cytokine and growth factor with antibody-based array
Cytokines and growth factors in the culture supernatants were detected using Human Cytokine Antibody Array 9 and Human Growth Factor Antibody Array 1 (RayBiotech, Inc., 
ELISA analysis
VEGF-C in the culture supernatants of tumor cells were quantified using human VEGF-C ELISA kit (Bender MedSystems, Austria) according to the manufacturer's protocol.
Assay of gene expression by real-time RT-PCR
The relative quantity of mRNA was determined by real-time RT-PCR as described previously (31) . GAPDH and EEF1A1 were chosen as reference genes, which were reported as the most reliable combination in cervical cancer (37) . The primer sequences are shown in the Supplementary Methods.
Assay of tube-formation
30 l/well matrigel (BD Biosciences) and 20 l/well serum-free ECM were mixed and polymerized in 96-well plate. Then, 6×10 3 HLECs in 100 l ECM were placed onto the layer of matrigel in each well. After a 3-h incubation, tube morphogenesis was assessed by phase-contrast microscopy. Tube-formation was quantified by measuring the total length of tube structures in 3 random fields. The average length of tube per field was calculated.
Flow cytometry
HLECs were incubated with PE-conjugated mouse anti-human VEGFR3 antibody (R&D) or isotype control at room temperature for 0.5 h. Flow cytometry was performed as described previously (31) . The expression index was calculated using the formula: mean fluorescence × percentage of positively stained cells (31, 38) .
Other Methods
Migration assay, immunoprecipitation (IP) and Chromatin immunoprecipitation (ChIP)
were performed using standard protocols. See Supplementary Methods for more details. 
Statistical Analysis
SPSS (version 13.0) software package was used for statistical analysis. Results were expressed as mean value ± standard error of the mean (SEM) and interpreted by one-way ANOVA. Correlation analyses were done using Spearman's rank test. Difference in the ratio of lymph-node metastasis was analyzed by Fisher exact probability test. Differences were considered to be statistically significant when P < 0.05. 
Results
Lymph-node metastasis of cervical cancer correlates with higher SIX1 expression at the primary site
To determine the effect of SIX1 on lymph-node metastasis, we first investigated whether lymph-node metastasis of cervical cancer correlated with the expression level of SIX1 in tumor. A significant increase in SIX1 expression was found at the primary site of cervical cancers with lymph-node metastasis (Fig. 1A) . Correspondingly, higher SIX1 expression correlated with increased peritumoral lymphatic vessel density (LVD) in cervical cancer ( 
SIX1 over-expression in tumor cells promotes lymph-node metastasis in vivo
To demonstrate the role of SIX1 in promoting lymph-node metastasis in cervical cancer, SIX1 was overexpressed in Siha cells, a CSCC cell line with low-level expression of SIX1 ( Fig. 2A) . The peritumoral LVD in orthotopically transplanted Siha-SIX1 tumors was significantly higher than in control Siha tumors ( 
SIX1 up-regulates the expression of VEGF-C in CSCC cells
Because SIX1 is a nuclear protein that cannot be released from tumor cells, we next investigated whether the effect of SIX1 might be mediated by released soluble factors that promote lymphangiogenesis. To do this, cytokines and growth factors in the culture supernatants of cervical cancer cells were detected using antibody-based arrays (supplementary Fig. 3 ). Other known lymphangiogenic factors absent from the arrays were analyzed by measuring mRNA levels of their corresponding genes (supplementary Fig. 4 ) (7, 8) . The results showed that SIX1 could up-regulate the expression of VEGF-C, but not other factors involved in lymphangiogenesis ( Fig. 3A and supplementary Fig. 4 ). The expression of the VEGF-C gene was significantly increased in Siha-SIX1 cells (Fig. 3B) .
Knocking down SIX1 expression in Siha-SIX1 cells (supplementary Fig. 5A ) significantly reduced the expression of VEGF-C (Fig. 3B) . The same effect was also observed in C33a cells (supplementary Fig. 5 ) and Caski cells (Fig. 3C) . Moreover, the analysis of human CSCC primary tumors indicated higher protein levels of VEGF-C in the SIX1-high group (Fig. 3D ) and the positive correlation between SIX1 and VEGF-C mRNA levels (Fig. 3E ).
These results demonstrate that SIX1 could promote the expression of VEGF-C in cervical 
were divided into four groups based on the HSCORE of SIX1 and VEGF-C staining. The rate of lymph-node metastasis in SIX1-high/VEGF-C-high patients was significantly higher than in SIX1-high/VEGF-C-low patients (Fig. 4D) , suggesting that VEGF-C was required for SIX1 to promote lymph-node metastasis. Consistent with this, when VEGF-C was knocked down in cervical cancer cells, lymph-node metastasis of orthotopic tumors was not affected by either increasing SIX1 expression in Siha or C33a cells (Fig. 4E and supplementary Fig.   11A ) or decreasing SIX1 expression in Caski cells (Fig. 4E and supplementary Fig. 11B ).
Taken together, these results demonstrate that the promotion of lymph-node metastasis by SIX1 is mediated by VEGF-C.
SIX1 coordinates with TGF-to promote VEGF-C expression
A recent study showed that SIX1 could bind to the VEGF-C gene promoter and directly activate transcription of VEGF-C (23). Interestingly, the relative levels of VEGF-C mRNA in SIX1-high clinical specimens were much higher than those in cell lines as shown in Figure 3B , 3C and 3E. To further confirm the differences between tumors in vivo and tumor cells cultured in vitro, we compared the expression of VEGF-C in cell lines with that in orthotopically transplanted tumors. Although SIX1 mRNA levels in tumors were similar to corresponding cells cultured in vitro (supplementary Fig. 12A) , VEGF-C mRNA levels in SIX1-expressing tumors were indeed significantly higher than those in SIX1-expressing cells cultured in vitro. However, VEGF-C mRNA levels in control Siha tumors and Caski-NshSIX1 tumors were similar to those in corresponding cells cultured in vitro (Fig. 5A and supplementary Fig. 12B ). In addition, low levels of VEGF-C were observed in some of the SIX1-high clinical samples as shown in Figure 4D . These results suggest that other 
factor(s) in the tumor milieu might be necessary for SIX1 to induce a high level of VEGF-C expression.
It has been shown that TGF-1 can induce VEGF-C expression in some cell types (13) , and that SIX1 can enhance TGF-signaling (20) . This raises the question whether SIX1
coordinates with TGF-to increase VEGF-C expression. To answer this question, we first analyzed the prevalence of TGF-members in CSCC specimens (supplementary Fig. 13) . The results showed that the protein levels of both TGF-1 and TGF-2 were lower in the SIX1-high/VEGFC-low groups, while the protein level of TGF-3 was low across all conditions (Fig. 5B) . Because each isoform of TGF-is capable of mediating TGFsignaling and exerts overlapping biological functions, the expression of TGF-was considered to be high if at least one member of the family was highly expressed in clinical samples (42, 43) . Interestingly, higher expression of TGF-correlated with higher expression of VEGF-C in SIX1-high clinical samples, but not in SIX1-low samples (Fig. 5C ). Consistent with this result, TGF-1 ( Fig. 5D and supplementary Fig. 14A ) and TGF-2 (data not shown) negligibly increased VEGF-C expression in the cervical cancer cell lines with low levels of SIX1 expression, but induced much higher expression of VEGF-C in SIX1-expressing cell lines in a dose-dependent manner. Moreover, when tumor cells were pre-treated with TGF-1, the promotion of tube-formation of HLECs by supernatants from SIX1-expressing cell cultures was significantly augmented, which was dependent on VEGF-C (supplementary lymphangiogenesis in vivo, we used T R1 shRNAs to inhibit TGF-signaling in tumor cells (supplementary Fig. 15A ). When T R1 was knocked down in SIX1-expressing cells, the differences in VEGF-C expression between tumors in vivo and tumor cells cultured in vitro were abolished (Fig. 5E and supplementary Fig. 15B ), indicating that TGF-signaling was responsible for further promoting VEGF-C expression in vivo. Consistently, the promoting effect of SIX1 on lymphangiogenesis ( Fig. 5F and supplementary Fig. 16A ) and lymph-node metastasis ( Fig. 5G and supplementary Fig. 16B ) was significantly inhibited when T R1 was knocked down. These results demonstrate that TGF-signaling is necessary for SIX1 to both induce higher expression of VEGF-C in tumor cells and promote lymphangiogenesis and lymph-node metastasis of cervical cancer cells in vivo.
SIX1 enhances the activation and effect of SMAD pathway to promote VEGF-C expression
TGF-induced much higher expression of VEGF-C in tumor cells with higher expression of SIX1 than in those with lower expression of SIX1. Therefore, we further investigated whether SIX1 might modulate the effects of TGF-. Both SMAD2 and SMAD3 could bind to the VEGF-C promoter after TGF-1 stimulation (Fig. 6A) . TGF-1 induced much higher phosphorylation levels of SMAD2 and SMAD3 in Siha-SIX1 cells and Caski control cells (Fig. 6B) . Consistent with this, the binding of SMAD2/3 to the VEGF-C promoter was significantly enhanced in SIX1-expressing tumor cells (Fig. 6C) . TGFactivates the SMAD-pathway mainly through T R1 (12) . Same as knocking down the expression of SMAD2 or SMAD3, knocking down T R1 expression could suppress TGF-1 induced VEGF-C expression in Siha-SIX1 and Caski cells (Fig. 6D and 17 ). Intriguingly, the expression of T R1 was up-regulated in Siha-SIX1 cells and down-regulated in Caski-NshSIX1 cells (Fig. 6E ). Higher expression of T R1 was also observed in SIX1-high tumors (supplementary Fig. 18 ), implying that SIX1 can enhance TGF-signaling by up-regulating T R1 expression.
SIX1 could also bind to the VEGF-C gene promoter (supplementary Fig. 19) . Knocking down the expression of SMAD2/3 did not reduce the binding of SIX1 to the VEGF-C promoter (supplementary Fig. 20) . Intriguingly, co-immunoprecipitation assays showed that SIX1 protein could interact with SMAD2 and SMAD3 (Fig. 6F) , suggesting that the interaction of SIX1 and SMAD2/3 might also be required for inducing higher expression of VEGF-C. Taken together, these results suggest that SIX1 can enhance TGF--induced activation of SMAD2/3, and might cooperate with the SMAD pathway to promote VEGF-C expression.
SIX1 modulates the effect of TGF-on lymphangiogenesis
The above data indicated that TGF-could stimulate SIX1-expressing tumor cells to increase the production of VEGF-C. However, TGF-has a negative effect on lymphangiogenesis due to its inhibitory effect on the expression of VEGFR3, the receptor of VEGF-C, in HLECs (15) . This led to the question whether VEGF-C could promote tube-formation of HLECs in the presence of TGF-. Indeed, TGF-1 could attenuate the promotion of HLEC tube-formation by VEGF-C (Fig. 7A) . Nevertheless, VEGF-C could attenuate the inhibitory effect of TGF-1 on VEGFR3 expression in a dose-dependent manner (Fig. 7B) , which is consistent with a previous finding that VEGF-C not only binds VEGFR3 but also stimulates VEGFR3 expression (44, 45) . Importantly, at higher concentrations Fig. 7C) or TGF-2 (data not shown). These results suggest that higher concentrations of VEGF-C can antagonize the inhibitory effect of TGF-on HLECs.
To clarify whether the increased VEGF-C in SIX1-expressing tumors could modulate the final effect of TGF-on lymphangiogenesis, we used the T R1 inhibitor LY364947 to block TGF-signaling in vivo. LY364947 negligibly affected VEGF-C expression in Siha-3.1 and Caski-NshSIX1 tumors (Fig. 7D) , but could increase LVD in these same tumors (Fig. 7E), suggesting that TGF-might inhibit lymphangiogenesis through its negative effect on LECs.
However, LY364947 treatment significantly reduced the expression of VEGF-C gene in SIX1-expressing tumors (Fig. 7D) , and also reduced LVD (Fig. 7E ) and lymph-node metastasis (Fig. 7F) . These results demonstrated that the final effect of TGF-on lymphangiogenesis of SIX1-expressing tumor was to promote this process. Moreover, when VEGF-C was knocked down in SIX1-expressing orthotopic tumors (Fig. 7D) , intraperitoneal injection of LY364947 increased LVD (Fig. 7E ). These results indicate that different levels of VEGF-C in tumor can result in different effects of TGF-on lymphangiogenesis. 
21
of lymphangiogenesis by SIX1 in vivo. Moreover, VEGF-C expression was required for SIX1 to promote lymph-node metastasis as shown by the analyses using human clinical samples and a mouse lymphatic metastasis model. Therefore, up-regulating VEGF-C expression is an important mechanism by which SIX1 promotes lymphangiogenesis and lymph-node metastasis in cervical carcinoma.
In this study, we show that SIX1 alone can slightly promote the expression of VEGF-C in tumor cells. This is consistent with a previous report demonstrating SIX1 can bind to the VEGF-C promoter and transcriptionally activate the VEGF-C gene in breast cancer cells (23) .
The regulatory effect of SIX1 alone on VEGF-C expression was limited. Intriguingly, both TGF-signaling and the overexpression of SIX1 were required for inducing significantly higher expression of VEGF-C in tumor cells. Therefore, the coordination of SIX1 and TGFis crucial for the high expression of VEGF-C in tumors.
Although TGF-has the potential to modulate VEGF-C expression (48) , its effect on VEGF-C expression in tumor cells remains uncertain. TGF-1 has been found to slightly increase VEGF-C expression in the pancreatic adenocarcinoma cell line PANC-1 (14), whereas no significant correlation has yet been found between the mRNA levels of TGF-1 and VEGF-C in adenocarcinoma of the small intestine (49) . The data in this study suggest that the differential effects of TGF-on VEGF-C expression in different tumor cells might be due to the different expression levels of SIX1 in those cells. Our data in this study show that SIX1 can coordinate with TGF-to induce higher expression of VEGF-C through two pathways. CAN-13-3598 22 expression of VEGF-C. Secondly, SIX1 could bind to the VEGF-C promoter and interact with SMAD2/3, suggesting that SIX1 might also cooperate with SMAD2/3 to modulate VEGF-C expression. In tumor cells with lower expression of SIX1, the expression of VEGF-C was inconspicuously influenced by TGF-stimulation, although SMAD2/3 could be phosphorylated and bind to the VEGF-C promoter. Therefore, SIX1 is necessary for TGF-to induce higher expression of the VEGF-C gene.
Although TGF-might promote lymphangiogenesis by promoting VEGF-C expression, it also has the potential to inhibit lymphangiogenesis by inhibiting VEGFR3 expression in LECs (15) . However, the data here revealed that the inhibitory effect of TGF-1 on LECs could be attenuated if the VEGF-C concentration was increased. VEGF-C not only binds VEGFR3 to directly promote lymphangiogenesis but also up-regulates VEGFR3 expression as shown by our data and others (44, 45) . The stimulation of HLECs with TGF-1 alone significantly inhibited tube-formation in vitro, whereas simply increasing the concentration of VEGF-C attenuated the inhibitory effect of TGF-1. Together, these results suggest that the excess production of VEGF-C is sufficient to antagonize the negative effect of TGF-on lymphangiogenesis. Therefore, the effect of TGF-on lymphangiogenesis might be negative, whereas overexpression of SIX1 in tumor cells might counteract the negative effects of TGF-on lymphangiogenesis in an indirect manner via VEGF-C. 
